Despite proven enhanced anti-tumor CD8+ T cells response following STING activation [29–31], we observed the drop in the number of CD8+ T cells within breast carcinoma TME following applied treatments which requires further explanation. The gene discussed is CD8A; the disease is breast carcinoma.